Xia - - Search Results

1

[Effect of HPV16 peptide vaccine in combination with paclitaxel-cisplatin chemotherapy on cervical cancer in vitro and in vivo].

Liao SJ, Hu XJ, Jiang XF, Han LF, Xia -, Wang W, Wang CY, Lu YP, Wang SX, Ma D. Liao SJ, et al. Among authors: xia. Zhonghua Yi Xue Za Zhi. 2010 Nov 23;90(43):3035-9. Zhonghua Yi Xue Za Zhi. 2010. PMID: 21211321 Chinese.

2

[Preparation of human papillomavirus 16 E7 peptide vaccine and its effectiveness in vitro and in vivo.].

Liao SJ, Hu XJ, Han LF, Jiang XF, Xia X, Wang W, Lu YP, Wang SX, Ma D. Liao SJ, et al. Among authors: xia x. Zhonghua Fu Chan Ke Za Zhi. 2009 Dec;44(12):903-8. Zhonghua Fu Chan Ke Za Zhi. 2009. PMID: 20193416 Chinese.

3

[Effects of human papillomavirus 16 E5 on malignancy of human cervical cancer cells and the mechanism there of].

Liao SJ, Deng DR, Xia X. Liao SJ, et al. Among authors: xia x. Zhonghua Yi Xue Za Zhi. 2008 Nov 25;88(43):3080-4. Zhonghua Yi Xue Za Zhi. 2008. PMID: 19192411 Chinese.

4

Synergistic efficacy in human ovarian cancer cells by histone deacetylase inhibitor TSA and proteasome inhibitor PS-341.

Fang Y, Hu Y, Wu P, Wang B, Tian Y, Xia X, Zhang Q, Chen T, Jiang X, Ma Q, Xu G, Wang S, Zhou J, Ma D, Meng L. Fang Y, et al. Among authors: xia x. Cancer Invest. 2011 May;29(4):247-52. doi: 10.3109/07357907.2010.496756. Epub 2011 Feb 23. Cancer Invest. 2011. PMID: 21345073 Free article.

5

Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer.

Xia X, Ma Q, Li X, Ji T, Chen P, Xu H, Li K, Fang Y, Weng D, Weng Y, Liao S, Han Z, Liu R, Zhu T, Wang S, Xu G, Meng L, Zhou J, Ma D. Xia X, et al. BMC Cancer. 2011 Sep 21;11:399. doi: 10.1186/1471-2407-11-399. BMC Cancer. 2011. PMID: 21933447 Free PMC article.

6

Silencing Wnt2B by siRNA interference inhibits metastasis and enhances chemotherapy sensitivity in ovarian cancer.

Wang H, Fan L, Xia X, Rao Y, Ma Q, Yang J, Lu Y, Wang C, Ma D, Huang X. Wang H, et al. Among authors: xia x. Int J Gynecol Cancer. 2012 Jun;22(5):755-61. doi: 10.1097/IGC.0b013e3182540284. Int J Gynecol Cancer. 2012. PMID: 22635028

7

Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer.

Ji T, Gong D, Han Z, Wei X, Yan Y, Ye F, Ding W, Wang J, Xia X, Li F, Hu W, Lu Y, Wang S, Zhou J, Ma D, Gao Q. Ji T, et al. Among authors: xia x. Cancer Lett. 2013 Dec 1;341(2):231-9. doi: 10.1016/j.canlet.2013.08.022. Epub 2013 Aug 17. Cancer Lett. 2013. PMID: 23962558

8

Zinc finger nucleases targeting the human papillomavirus E7 oncogene induce E7 disruption and a transformed phenotype in HPV16/18-positive cervical cancer cells.

Ding W, Hu Z, Zhu D, Jiang X, Yu L, Wang X, Zhang C, Wang L, Ji T, Li K, He D, Xia X, Liu D, Zhou J, Ma D, Wang H. Ding W, et al. Among authors: xia x. Clin Cancer Res. 2014 Dec 15;20(24):6495-503. doi: 10.1158/1078-0432.CCR-14-0250. Epub 2014 Oct 21. Clin Cancer Res. 2014. PMID: 25336692

9

[A retrospective study of tumor and fertility outcomes after fertility-sparing surgical treatment of patients with borderline ovarian tumors].

Liu F, Hu DH, Zhang YF, Wang B, Huang K, Wang CY, Xia XY. Liu F, et al. Among authors: xia xy. Zhonghua Yi Xue Za Zhi. 2017 Dec 19;97(47):3699-3703. doi: 10.3760/cma.j.issn.0376-2491.2017.47.004. Zhonghua Yi Xue Za Zhi. 2017. PMID: 29325322 Chinese.

10

Implication of the Akt2/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells.

Weng D, Song X, Xing H, Ma X, Xia X, Weng Y, Zhou J, Xu G, Meng L, Zhu T, Wang S, Ma D. Weng D, et al. Among authors: xia x. Cancer Lett. 2009 Jan 18;273(2):257-65. doi: 10.1016/j.canlet.2008.08.027. Epub 2008 Oct 7. Cancer Lett. 2009. PMID: 18842333

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

97,283 results

Search Page

Filters